AVISE CTD

The Advanced Rheumatology Test for the Differential Diagnosis of SLE


AVISE CTD is an advanced autoimmune rheumatic disease test, powered by patented Cell-Bound Complement Activation Products (CB-CAPs), specifically designed to aid in the differential diagnosis of systemic lupus erythematosus (SLE).

THE BETTER COMPLEMENT TEST - Offering 22% greater sensitivity compared to low C3/C4.

The Advanced Rheumatology Test for the Differential Diagnosis of SLE.

Clinical Utility

There are many clinical scenarios that can benefit from the AVISE CTD test including:

  • Patient Triage
  • Assessment of ANA positive referrals
  • Patients with clinical suspicion of a connective tissue disease but insufficient criteria for diagnosis
  • Assessment of patients with overlapping symptoms
  • Observation of Undifferentiated Connective Tissue Disease
  • ANA positive fibromyalgia patients with clinical suspicion of underlying autoimmune inflammatory disease
 

Assays included:

AVISE CTD contains the patented SLE biomarkers, CB-CAPs, which help to offer a 22% greater sensitivity compared to C3/C4, and 48% greater sensitivity compared to anti-dsDNA.









Understanding how the AVISE Index Value is Calculated:


[goal id="3700"]